Financial Analysis: SiBone (NASDAQ:SIBN) versus Advanced Biomedical Technologies (OTCMKTS:ABMT)

SiBone (NASDAQ:SIBN) and Advanced Biomedical Technologies (OTCMKTS:ABMT) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, dividends, earnings and risk.

Profitability

This table compares SiBone and Advanced Biomedical Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SiBone	-8.10%	-9.56%	-7.06%
Advanced Biomedical Technologies	N/A	N/A	N/A

Risk and Volatility

SiBone has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500. Comparatively, Advanced Biomedical Technologies has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500.

Institutional and Insider Ownership

98.1% of SiBone shares are held by institutional investors. 4.0% of SiBone shares are held by company insiders. Comparatively, 34.1% of Advanced Biomedical Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for SiBone and Advanced Biomedical Technologies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1	0	6	0	2.71
Advanced Biomedical Technologies	0	0	0	0	0.00

SiBone currently has a consensus target price of $23.00, indicating a potential upside of 52.12%. Given SiBone’s stronger consensus rating and higher probable upside, equities analysts clearly believe SiBone is more favorable than Advanced Biomedical Technologies.

Valuation & Earnings

This table compares SiBone and Advanced Biomedical Technologies”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$200.93 million	3.34	-$18.90 million	($0.39)	-38.77
Advanced Biomedical Technologies	N/A	N/A	N/A	N/A	N/A

Advanced Biomedical Technologies has lower revenue, but higher earnings than SiBone.

About SiBone

SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

About Advanced Biomedical Technologies

Advanced Biomedical Technologies, Inc., a development stage company, designs, develops, manufactures, and markets biomaterial internal fixation devices. It offers polymer osteosynthesis devices, such as surgical screws, binding wires, rods, and related medical devices for the treatment of orthopedic trauma, sports-related medical treatment, cartilage repair, and related treatments, as well as for reconstructive dental procedures. The company was formerly known as Geostar Mineral Corporation and changed its name to Advanced Biomedical Technologies, Inc. in March 2009. Advanced Biomedical Technologies, Inc. was founded in 2002 and is based in New York, New York.